Background
Methods
Number | Percent | |
---|---|---|
Total number of patients | 22 | |
Males | 15 | 68 |
Females | 7 | 32 |
Primitive lung cancer | 13 | 59 |
NSCLC | 12 | 54 |
SCLC | 1 | 4 |
PET Positive, No histological report | 2 | 9 |
METASTASIS | 7 | 32 |
Colon Cancer | 2 | 10 |
Rectal Cancer | 2 | 10 |
Breast Cancer | 1 | 4 |
Carcinoma of the Uterus | 1 | 4 |
Oropharyngeal Cancer | 1 | 4 |
Histology | ||
Adenocacinoma | 13 | 59 |
Squamous Carcinoma | 6 | 27 |
SCLC | 1 | 5 |
PET Positive, No histological report | 2 | 9 |
Performace status | ||
0 | 12 | 55 |
1 | 9 | 41 |
2 | 1 | 4 |
Status of patients | ||
Patients with only one site of disease | 4 | 15 |
Patients with others site of disease, but stable | 23 | 85 |
Chemotherapy after re-irradiation | ||
Yes | 8 | 30 |
No | 19 | 70 |
Diagnosis of recurrence disease | ||
PET-CT 18FDG | 19 | 70 |
TBCT | 8 | 30 |
Histological Exam | 0 | 0 |
Localization of lesions | ||
Peripheral | 23 | 85 |
Central | 4 | 15 |
Treatment plan
Number | Range | |
---|---|---|
Total number of lesions | 27 | |
Volume | ||
Medium Volume (cc) | 30,8 | 2,7–260,7 |
Diameter | ||
Medium Diameter (cm) | 3,7 | 1,7–7,9 |
Localization of lesions | ||
Out-field | 6 | 22 |
In-field | 21 | 78 |
Doses
Number of fractions of the first treatment (SBRT) | Number | Percent |
---|---|---|
Single Fraction | ||
30 Gy/ 1 fr | 11 | 42 |
23 Gy/1 fr | 3 | 11 |
Multiple Fractions | ||
45 Gy/ 3fr | 3 | 11 |
50 Gy/5 fr | 3 | 11 |
60 Gy/ 30 fr
a
| 5 | 18 |
30 Gy/ 10 fr
b
| 2 | 7 |
Number of fractions of the re-irradiation (SBRT) | ||
Single Fraction | ||
30 Gy/ 1 fr | 4 | 15 |
23 Gy/1 fr | 3 | 11 |
Multiple Fractions | ||
54 Gy/ 3 fr | 3 | 11 |
45 Gy / 3fr | 5 | 18 |
50 Gy/ 5fr | 8 | 30 |
30Gy/fr 5 | 4 | 15 |
Medium biological effective dose (10Gy) (BED10) | Dose | Range |
I Treatment | 97,2 Gy | 40–120 |
Re-Irradiation | 100,6 Gy | 48–151,2 |
Medium equivalent dose in 2 Gy (10 Gy) (EQD2) | DOSES | RANGE |
I treatment | 81 Gy | 32,5–100 Gy |
Re-Irradiation | 93,8 Gy | 40–126 Gy |
Cumulative medium BED (10) | 197,8 Gy | 88–271,2 Gy |
Cumulative medium EQD2 (10) | 164,8 Gy | 72,5–226 Gy |
Median biological effective dose (10Gy) (BED10) | Doses | Range |
I Treatment | 112,5 Gy | 40–120 Gy |
Re-Irradiation | 100 Gy | 48–151,2 Gy |
Median equivalent dose in 2 Gy (10 Gy) (EQD2) | Doses | Range |
I treatment | 93,8 Gy | 32,5–100 Gy |
Re-Irradiation | 83,3 Gy | 40–126 Gy |
Cumulative median bed (10) | 200 Gy | 88–271,2 Gy |
Cumulative median EQD2 (10) | 166,7 Gy | 72,5.226 Gy |
Follow up
Statistical analysis
Results
1 Year | 2 Years | |
---|---|---|
aLC | 67% | 54% |
bPFS | 45% | 39% |
cDSS | 81% | 63% |
dOS | 81% | 63% |
aAcute | bLate | |||||||
---|---|---|---|---|---|---|---|---|
Grade | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
Dyspnea | 4 | 1 | 1 | 0 | 1 | 4 | 1 | 0 |
Chest pain | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
Laryngeal hemorrhage | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Peripheral sensory neuropathy | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Cough | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Productive cough | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pulmonary fibrosis | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
Rib fracture | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Pleural effusion | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Gastro-esophageal reflux | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Soft tissue necrosis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
LC | PFS | DSS | OS | |
---|---|---|---|---|
aHistology | 0,6 | 0,3 | 0,3 | 0,3 |
bStatus of patients | 0,7 | 0,5 | 0,3 | 0,3 |
cNumber of fractions | 0,05 | 0,09 | 0,06 | 0,06 |
dMedian EQD2 (10 GY) of re-irradiation | 0,4 | 0,4 | 0,7 | 0,7 |
eMedian BED2 (10) of re-irradiation | 0,4 | 0,4 | 0,7 | 0,7 |
fMedian EQD2 (10 GY) cumulative | 0,03 | 0,03 | 0,1 | 0,1 |
gMedian BED (10) cumulative | 0,02 | 0,05 | 0,08 | 0,08 |
hCHT after re-irradiation | 0,2 | 0,09 | 0,8 | 0,8 |
iMedian time between both treatments | 0,4 | 0,5 | 0,6 | 0,6 |
jMedian time of first progression of the disease | 0,6 | 0,5 | 0,3 | 0,3 |